Urothelial Cancer Clinical Trials

16 studies are recruiting for urothelial cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

   This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this can…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Samsun Clinic - Ridley-Tree Cancer Center, Santa Barbara, California

   Locations

   14 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07566156 on ClinicalTrials.gov

2. Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy

   The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro)…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT07548476 on ClinicalTrials.gov

3. AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

   This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with loc…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Avenzo Therapeutics Recruiting Site, Gilbert, Arizona

   Locations

   19 in total

   Run by

   Avenzo Therapeutics, Inc.

   See if you can join NCT07038343 on ClinicalTrials.gov

4. Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue

   Background: Urothelial cancer is cancer of the bladder, ureter, and urethra. Researchers want to better understand what changes in a person s cells and genes cause this cancer to form. This may help them find new ways to treat it. Objective: - To perform DNA sequencing to help researchers learn the…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT02379429 on ClinicalTrials.gov

5. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

   This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC San Diego Moores Cancer Center, San Diego, California

   Locations

   9 in total

   Run by

   Sutro Biopharma, Inc.

   See if you can join NCT07227168 on ClinicalTrials.gov

6. BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

   This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Avenzo Therapeutics Recruiting Site, San Francisco, California

   Locations

   14 in total

   Run by

   Avenzo Therapeutics, Inc.

   See if you can join NCT07193511 on ClinicalTrials.gov

7. Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

   This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Research Site, Los Angeles, California

   Locations

   100 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT07129993 on ClinicalTrials.gov

8. Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

   This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Highlands Oncology Group, PA, Fayetteville, Arkansas

   Locations

   153 in total

   Run by

   Pfizer

   See if you can join NCT07421700 on ClinicalTrials.gov

9. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

   TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

   Stage

   Phase 2

   Ages

   18 to 130

   Site

   Research Site, Los Angeles, California

   Locations

   96 in total

   Run by

   AstraZeneca

   See if you can join NCT05489211 on ClinicalTrials.gov

10. A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

    Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare. Some GU tumors are so rare that they are not included in treatment studies or tissu…

    Stage

    Not phased

    Ages

    18 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT04923178 on ClinicalTrials.gov

11. Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

    A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Palo Alto Center-Palo Alto Medical Foundation Research Institute, Palo Alto, California

    Locations

    163 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07106762 on ClinicalTrials.gov

12. DK222 Study at Hopkins

    This Phase 1 clinical trial will test a new drug called [18F]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the body, how long it stays in the body, and how much radiation it gives off. [18F]DK222 is designed to attach strongly and specifically to a prot…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Johns Hopkins Hospital, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT07140315 on ClinicalTrials.gov

13. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

    Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current standard of care treatment for their stage of disease would…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Dan Zandberg

    See if you can join NCT04114136 on ClinicalTrials.gov

14. SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

    This Phase II clinical trial, titled "A Phase II Trial of Sequential Gemcitabine and Mitomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (SUMMIT)," aims to evaluate the safety and effectiveness of a combination chemotherapy treatment for patients with favorable papi…

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    Rutgers Cancer Institute, New Brunswick, New Jersey

    Run by

    Rutgers, The State University of New Jersey

    See if you can join NCT06822010 on ClinicalTrials.gov

15. Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer

    The purpose of this study is to determine if analysis of DNA and protein material found in urine will be useful in the detection of urothelial cancer of the bladder and kidney. This analysis may be helpful to determine if how a particular cancer will act regarding remission and recurrence

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lahey Clinic, Inc., Burlington, Massachusetts

    Run by

    Lahey Clinic

    See if you can join NCT00872495 on ClinicalTrials.gov

16. Sacituzumab Govitecan Plus EV in Metastatic UC

    Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC). In Phase II of the study, patients in one of the two cohorts will receive Sacituzumab Govitecan, Enfortumab Vedotin…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04724018 on ClinicalTrials.gov